In:
Dermatology, S. Karger AG, Vol. 213, No. 4 ( 2006), p. 313-318
Abstract:
〈 i 〉 Background: 〈 /i 〉 Controlled studies established the efficacy and good tolerability of pimecrolimus cream 1% for the treatment of atopic dermatitis but they may not reflect real-life use. 〈 i 〉 Objective: 〈 /i 〉 To evaluate the efficacy, tolerability and cosmetic acceptance of a pimecrolimus-based regimen in daily practice in Switzerland. 〈 i 〉 Methods: 〈 /i 〉 This was a 6-month, open-label, multicentre study in 109 patients (55% ≧18 years) with atopic dermatitis. Pimecrolimus cream 1% was incorporated into patients’ standard treatment protocols. 〈 i 〉 Results: 〈 /i 〉 The pimecrolimus-based treatment was well tolerated and produced disease improvement in 65.7% of patients. It was particularly effective on the face (improvement rate: 75.0%). Mean pimecrolimus consumption decreased from 6.4 g/day (months 1–3) to 4.0 g/day (months 3–6) as disease improved. Most patients (74.1%) rated their disease control as ‘complete’ or ‘good’ and 90% were highly satisfied with the cream formulation. 〈 i 〉 Conclusion: 〈 /i 〉 The use of a pimecrolimus-based regimen in everyday practice was effective, well tolerated and well accepted by patients.
Type of Medium:
Online Resource
ISSN:
1018-8665
,
1421-9832
Language:
English
Publisher:
S. Karger AG
Publication Date:
2006
detail.hit.zdb_id:
1482189-8
